



# aTyr Pharma

## **aTyr Pharma to Present at Jefferies 2018 Global Healthcare Conference**

May 31, 2018

SAN DIEGO, May 31, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., President and Chief Executive Officer, will present at the Jefferies 2018 Global Healthcare Conference in New York City on Thursday, June 7, 2018 at 9:30 a.m. Eastern Time.

Links to a live audio webcast and replay of the presentation may be accessed on the aTyr website events page at: <http://investors.atyrpharma.com/events-and-webcasts>. An audio replay will be available for 90 days following the event.

### **About aTyr Pharma**

aTyr is a clinical-stage biotechnology company engaged in the discovery and clinical development of innovative medicines using its knowledge of tRNA synthetase biology. The company is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase (HARS) gene family. aTyr's clinical stage ATYR1923 candidate augments the Resokine pathway and is designed to temper immune engagement in interstitial lung diseases. aTyr's immuno-oncology research program targets the Resokine pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit <http://www.atyrpharma.com>.

### **Contact:**

#### **Mark Johnson**

Sr. Director, Investor Relations

[mjohnson@atyrpharma.com](mailto:mjohnson@atyrpharma.com)

858-223-1163

[Primary Logo](#)

Source: aTyr Pharma, Inc.